Chemical Structure : RM-3-22
货号: PC-24921Not For Human Use, Lab Use Only.
RM-3-22 is a TAZQ-based hydroxamic acid derivative and potent HDAC inhibitor with IC50 of 49.9 nM, 68.5 nM, and 12.9 nM for HDAC1, HDAC3, and HDAC6 isoforms respectively.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
RM-3-22 is a TAZQ-based hydroxamic acid derivative and potent HDAC inhibitor with IC50 of 49.9 nM, 68.5 nM, and 12.9 nM for HDAC1, HDAC3, and HDAC6 isoforms respectively.
RM-3-22 displays 97, 126-, 47-, 316-, and 334-folds higher selectivity towards HDAC6 isoform in comparison to HDAC2, HDAC4, HDAC5, HDAC7, and HDAC9, respectively.
RM-3-22 induces the cytotoxicity of different cancer cell lines, especially the lung cancer cell line A549 (IC50=0.8 uM).
RM-3-22 induces autophagy pathway through the inhibition of PI3K/Akt/mTOR.
RM-3-22 significantly induces caspase-dependent apoptosis in A549 cells.
RM-3-22 treatment causes cell cycle arrest in the G2/M phase by the disruption of cyclin B and CDC2 in A549 cells.
RM-3-22 enhances the expression of the tumor suppressor gene FTH1, which is positively correlated with apoptosis and autophagy pathway.
RM-3-22 suppresses tumor growth by inducing autophagy, apoptosis, cell cycle arrest, and FTH1 upregulation.
分子量 | 404.47 | |
分子式 | C23H24N4O3 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
1. Sharma R, et al. Eur J Med Chem. 2022 Oct 5;240:114602.
2. Chatterjee E, et al. Front Pharmacol. 2025 Jun 5;16:1544666.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright